Fecal Bile Acid to Predict Recurrence in C. Difficile Infection Fecal Bile Acid to Predict Recurrence in C. Difficile Infection
This study investigated how gut microbiota-bile acid interactions relate to the pathogenesis of C. difficile infection. Could fecal bile acids have potential as biomarkers to predict CDI recurrence?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

First FDA-Approved Fecal-Based Treatment Helps Fight C. difficile
THURSDAY, Dec. 1, 2022 -- The U.S. Food and Drug Administration on Wednesday approved the first fecal microbiota treatment, aimed at helping adults battling tough-to-treat Clostridioides difficile infections (CDIs). " Today ' s approval of Rebyota is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 1, 2022 Category: General Medicine Source Type: news

Fecal-Based Treatment, Rebyota. Helps Fight C. difficile
THURSDAY, Dec. 1, 2022 -- The U.S. Food and Drug Administration on Wednesday approved the first fecal microbiota treatment, aimed at helping adults battling tough-to-treat Clostridioides difficile infections (CDIs). " Today ' s approval of Rebyota is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 1, 2022 Category: General Medicine Source Type: news

FDA OKs First Fecal Transplant Therapy for Recurrent C difficile FDA OKs First Fecal Transplant Therapy for Recurrent C difficile
Rebyota, a microbiota-based live biotherapeutic prepared from human stool, is intended for use after an individual has completed antibiotic treatment for recurrent C difficile infection.FDA Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 1, 2022 Category: Internal Medicine Tags: Gastroenterology News Alert Source Type: news

First FDA-Approved Fecal-Based Treatment, Rebyota, Helps Fight a Tough Superbug
THURSDAY, Dec. 1, 2022 -- The U.S. Food and Drug Administration on Wednesday approved the first fecal microbiota treatment, aimed at helping adults battling tough-to-treat Clostridium difficile (C. diff) infections. " Today ' s approval of Rebyota is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 1, 2022 Category: General Medicine Source Type: news

Learn To “See” C. Difficile To Protect Yourself From This Serious Infection
C. diff causes almost half a million  infections yearly. Restoring normal gut microbiome is the focus of new treatments for C diff infections, which follow courses of antibiotics. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 28, 2022 Category: Pharmaceuticals Authors: Judy Stone, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?
Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI) have been updated. However, in addition to the clinical efficacy data, the drug of choice should ideally represent optimal antimicrobial stewardship, with an emphasis on rapid restoration of the gut microbiota to minimize the risk of infection relapses. Oral administration of metronidazole results in low concentration in stool, and interaction with fecal microbiota reduces its antimicrobial bioactivity. Reported elevated minimum inhibitory concentrations of metronidazole in epidemic C. difficile ribotypes and the emergence of plasmi...
Source: Current Awareness Service for Health (CASH) - November 15, 2022 Category: Consumer Health News Source Type: news

Houston, We Have a Problem: Reports of Clostridioides difficile Isolates With Reduced Vancomycin Susceptibility.
During the past 4 decades, oral vancomycin has been a mainstay of Clostridioides difficile infection (CDI) therapy with no reports of treatment failure due to emergence of vancomycin resistance. However, C. difficile isolates with high-level phenotypic resistance to vancomycin have recently been reported in 3 distinct geographic regions. There is an urgent need for surveillance to determine if strains with reduced vancomycin susceptibility are circulating in other areas. In a Cleveland-area hospital, screening of 176 CDI stool specimens yielded no C. difficile isolates with reduced vancomycin susceptibility and highlighted...
Source: Current Awareness Service for Health (CASH) - November 15, 2022 Category: Consumer Health News Source Type: news

13 Highlights From ACG 2022 13 Highlights From ACG 2022
Dr David Johnson shares the latest data from this year ' s meeting, which range from novel treatments for C difficile to the use of virtual reality in treating dyspepsia.Medscape Gastroenterology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 1, 2022 Category: Allergy & Immunology Tags: Gastroenterology Commentary Source Type: news

Oral FMT on Par With Colonic FMT for Recurrent C difficile Oral FMT on Par With Colonic FMT for Recurrent C difficile
Freeze-dried, encapsulated fecal microbiota transplantation (FMT) has a safety and effectiveness profile similar to that of liquid colonic FMT, without the procedural risks of colonoscopy.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 31, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

RBX2660 Shows Promise in Breaking the Cycle of Recurrent C diff RBX2660 Shows Promise in Breaking the Cycle of Recurrent C diff
Building on the success seen with fecal microbiota transplantation, this experimental treatment lowered the rates of recurrent C difficile infections.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 28, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
If approved, SER-109 expected to be the first-ever FDA-approved oral microbiome therapeutic PDUFA target action date is April 26, 2023, with anticipated launch soon thereafter FDA advised that they are not currently planning to hold an Advisory... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - October 26, 2022 Category: Drugs & Pharmacology Source Type: news

Early FMT Shows Promise for Preventing Recurrent C difficile Early FMT Shows Promise for Preventing Recurrent C difficile
The results of this trial suggest that microbiota restoration might be necessary to obtain sustained resolution following C difficile infection.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2022 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Powerful physics tool could help scientists understand complex ecosystems
Your gut is home to microbial madness. Hundreds of trillions of bacteria belonging to countless species interact with one another in complex ways that can both keep you healthy and cause disease . Teasing out these interactions would seem an impossible task. Now, microbiologists have found help from an unlikely source: physics. A new experiment suggests a powerful concept known as a phase transition can predict how complex ecosystems—like those composed of the bacteria in your belly—behave. The finding could help us keep our guts healthy and even protect other complex ecosystems such as rainforests and ...
Source: ScienceNOW - October 6, 2022 Category: Science Source Type: news

Host and microbial-derived metabolites for Clostridioides difficile infection: Contributions, mechanisms and potential applications
Clostridioides difficile infection (CDI), which mostly occurs in hospitalized patients, is the most common and costly health care-associated disease. However, the biology of C. difficile remains incompletely understood. Current therapeutics are still challenged by the frequent recurrence of CDI. Advances in metabolomics facilitate our understanding of the etiology of CDI, which is not merely an alteration in the structure of the gut microbial community but also a dysbiosis metabolic setting promoting the germination, expansion and virulence of C. difficile. Therefore, we summarized the gut microbial and metabolic profiles ...
Source: Current Awareness Service for Health (CASH) - September 30, 2022 Category: Consumer Health News Source Type: news